Strata Critical Medical, Inc. A Comprehensive Look at the 2025 Annual Report

Business Overview

Strata Critical Medical, Inc. focuses on two vital areas: Specialized Logistics for time-sensitive medical materials and Clinical Services, especially Transplant Clinical support and other critical care operations. The year 2025 marked a significant transformation for the company. Strata strategically expanded its clinical services by acquiring Keystone Perfusion Services LLC in September 2025 for approximately $35 million, greatly strengthening its critical care offerings. At the same time, to streamline operations and concentrate on its main strengths, Strata sold its non-core "Passenger Business" in August 2025 for $15 million.

Several key trends shape the critical medical and logistics industries:

• Aging Population and Chronic Diseases: These factors are driving increased demand for specialized medical services and logistics.
• Technological Advancements: While offering chances for greater efficiency, these advancements also require ongoing investment.
• Healthcare Regulatory Scrutiny: Strict rules, particularly around patient data privacy (like HIPAA) and medical device transport, could raise operating expenses and compliance demands.
• Supply Chain Volatility: This ongoing challenge continues to threaten the availability and cost of essential medical supplies.

Financial Performance

Strata Critical Medical, Inc. reported total revenue of $125 million for 2025, a 5% increase from $119 million in 2024. The Keystone acquisition primarily drove this growth, counteracting the sale of the Passenger Business. Despite higher revenue, the company posted a net loss of $8 million in 2025, up from a $5 million net loss in 2024. This larger loss stemmed mainly from expenses related to the acquisition and increased operating costs.

Key financial highlights for 2025 include:

• Gross Profit: $35 million, resulting in a 28% gross margin.
• Adjusted EBITDA: $10 million, which offers a clearer view of core operational profitability before non-cash and one-time expenses.
• Stock-based compensation expenses, part of general and administrative costs, rose to $3 million from $2 million in 2024, reflecting greater employee incentives.

As of December 31, 2025, the company's market capitalization stood at approximately $250 million, with 87 million shares outstanding.

Risk Factors

Strata faces several key risks that could impact its financial performance and stock price:

• Customer Concentration: A significant portion of Strata's revenue comes from a single customer. "Customer One" generated 28% of total revenue in 2025 (30% in 2024). Losing this major customer could severely reduce revenue.
• Supplier Concentration: Strata heavily depends on "Supplier One" for essential components, which made up 25% of its cost of goods sold in 2025. This reliance makes the company vulnerable to supply chain disruptions or price hikes from this single source.
• Pending Litigation: A class-action lawsuit filed in early 2024 alleging service discrepancies is ongoing. While management believes these claims lack merit, the company still faces potential legal costs and an adverse judgment, estimated at up to $5 million.
• Warrant Dilution: The company has 10 million outstanding warrants (SRTAW) with an exercise price of $3.00 per share. If investors exercise these warrants, they could increase the number of common shares by approximately 11.5%, potentially diluting the value of existing shares.
• Smaller Reporting Company Status: As a "Smaller Reporting Company," Strata has fewer public disclosure requirements than larger companies. This may mean less transparency for investors. Additionally, smaller companies often experience higher stock price volatility and may have fewer resources to manage complex market conditions.

Management Discussion

In 2025, Strata took significant strategic steps to sharpen its business focus and boost long-term profitability. The acquisition of Keystone Perfusion Services LLC stands out as a major strategic success. This move expanded Strata's market presence and capabilities in high-demand critical medical clinical services, and we expect it to add $20 million in annual revenue moving forward. Simultaneously, selling the "Passenger Business" allowed Strata to concentrate on its more profitable and strategically aligned critical medical and logistics segments, thereby improving operational efficiency.

These strategic decisions—acquiring Keystone and selling the Passenger Business—clearly demonstrate Strata's commitment to focusing on its core critical medical and logistics operations. This shift aims to build a more specialized, efficient, and potentially more profitable company. Our ongoing equity incentive plan helps align the interests of management and employees with long-term shareholder value, supporting this strategic direction. The net loss in 2025 primarily resulted from one-time acquisition costs and higher general and administrative expenses tied to these strategic changes.

Financial Health

As of December 31, 2025, Strata maintained a solid financial position with $12 million in cash and cash equivalents. The company's total debt amounted to $45 million, which included a term loan and capital lease obligations. Shareholders' equity reached $80 million by year-end, consisting of common stock, additional paid-in capital, and retained earnings.

A significant positive development happened after the year closed: in January 2026, Strata secured a new $20 million asset-backed revolving credit facility (ABL facility). This flexible credit line improves the company's ability to manage its day-to-day cash flow, finance future growth, and provides a strong safeguard against short-term cash needs.

Future Outlook

The new ABL facility, secured in early 2026, gives Strata greater financial flexibility to pursue its strategic goals. This includes potentially making more acquisitions or growing its core businesses organically. Management expects the integration of Keystone Perfusion Services to boost revenue and create operational efficiencies in 2026. Strata is dedicated to improving profitability by using its specialized knowledge and streamlining its operations.

Competitive Position

By acquiring Keystone Perfusion Services, Strata has significantly bolstered its competitive standing in the specialized clinical services market, especially in transplant and critical care. This strategic action enables the company to offer a broader range of services, potentially growing its market share and creating opportunities to sell additional services within its logistics segment. Strata's main competitors include regional specialized logistics providers and larger healthcare service conglomerates.